Legal
Filter News
Found 9,428 articles
-
Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.
-
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
6/15/2021
Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities ("Sun") resolving patent litigation related to Korlym.
-
Centene Reaches No-Fault Agreements with Ohio and Mississippi to Resolve Pharmacy Subsidiary Claims
6/14/2021
Centene Corporation (NYSE: CNC) today announced that it has reached no-fault agreements with the Attorneys General of Ohio and Mississippi to resolve claims made by the states related to services provided by Envolve Pharmacy Solutions, Inc.
-
Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
6/11/2021
Endo International plc today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals.
-
The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.
-
AngioSoma, Inc., Soon To Be GlobeStar Therapeutics Corporation, Retains Sichenzia Ross Ference, LLP As Outside Securities Counsel
6/9/2021
Law Firm Selected Because of Their Commitment to Excellence and Securities Expertise.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
United claims Liquidia and a former employee misappropriated its trade secrets such as regulatory submissions and detailed financial forecasts for its inhaled treprostinil.
-
An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.
-
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
6/7/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.
-
It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.
-
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
-
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
6/3/2021
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.
-
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi
6/3/2021
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada's approval of Medunik's New Drug Submission (NDS) for Ruzurgi®.
-
The early termination of the trials places a damper on Novartis' hopes of competing even further with Regeneron Pharmaceuticals' retinal disease drug Eylea.
-
The FDA has a massive backlog of site inspections due to the pandemic. To address the problem, the agency made its Resiliency Roadmap outlining its priorities.
-
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
5/28/2021
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal's™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
-
Lilly said it is cooperating fully with the DOJ and is in the process of conducting its own investigation into the allegations made against the company.
-
Bayer announces five-point plan to effectively address potential future Roundup™ claims
5/26/2021
Bayer announced today a series of actions it plans to implement following the denial of the motion to preliminarily approve the Roundup™ class settlement agreement, designed to address potential future litigation, by Judge Vince Chhabria of the U.S. District Court for the Northern District of California.
-
Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH
5/26/2021
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced an agreement with former LungFit ® PH commercial licensee, Circassia Group plc.